Bristol Myers Squibb Company has been preparing for a long time to launch its most recently approved product, the TYK2 inhibitor Sotyktu (deucravacitinib). And with its first dermatology drug, the company has set a big goal – to become the new standard of care for treating psoriasis with an oral therapy, unseating Amgen, Inc.’s established PDE4 inhibitor Otezla (apremilast).
BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu
TYK2 Inhibitor Grows Bristol’s Immunology Franchise
Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.
More from New Products
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.